Study | No of patients | Males (n (%)) | Study period | Grades I, II (%) | Agent |
---|---|---|---|---|---|
Jahan et al43 | 23 | 8 (34.8) | 1998–1999 | 30.4 | EVOH |
FDA trial31 | 46 | 20 (43.5) | NA | 54.3 | EVOH |
Joseph et al44 | 5 | 2 (40) | 2004–2005 | NA | EVOH |
Leonardi et al45* | 34 | 17 (50) | NA | 0.0 | EVOH (all), (NBCA, coil in 1 patient) |
Tevah et al.46† | 24 | 11 (45.8) | 2004–2005 | NA | EVOH (all), (NBCA in 2 patients) |
Pierot et al47 | 48 | 23 (47.9) | 2003–2005 | NA | EVOH |
Perez-Higueras et al7 | 45 | 22 (48.9) | 1999–2004 | NA | EVOH |
Weber et al48 | 47 | 31 (66) | 2002–2004 | 53.2 | EVOH |
van Rooij et al13‡ | 44 | 26 (59.1) | 2000–2005 | NA | EVOH (all), (NBCA in 2 patients) |
Katsaridis et al49§ | 101 | 58 (57.4) | 2004–2007 | 24.8 | EVOH (all), PVA (15.1%), NBCA (7.8%), coil (0.9%) |
Velat et al40 | 20 | 10 (50) | 2002–2006 | 75.0 | EVOH |
Panagiotopoulos 6 | 82 | 41 (50) | 2002–2008 | 72.0 | EVOH |
Geo et al50 | 115 | 72 (62.6) | 2003–2007 | 33.0 | EVOH |
Pan et al51 | 20 | 14 (70) | 2006–2008 | 45.0 | EVOH |
Loh et al41 | 54 | 24 (44.4) | 2001–2003 | 53.7 | EVOH |
Maimon et al52 ¶** | 43 | 27 (62.8) | 2006–2007 | 18.6 | EVOH (all), NBCA in 3 patients |
Abud et al53 | 17 | 8 (47.1) | 2008–2009 | 47.1 | EVOH |
Xu et al54 | 86 | 51 (59.3) | 2004–2007 | 18.6 | EVOH |
Saatci et al55†† | 350 | 206 (58.9) | 1999–2008 | 45.1 | EVOH (all), NBCA (12%) |
van Rooij et al14 | 24 | 17 (70.8) | 2008–2011 | 83.3 | EVOH |
Jadadeesan et al56 | 4 | 1 (25) | 2002–2004 | 25.0 | EVOH |
In addition to EVOH, the following agents were used as a complementary agent(s):
*NBCA and coil were used in one case.
†NBCA was used in 2 cases.
‡NBCA was used in 2 cases.
§Particle in 15.1%, NBCA in 7.8%, and coil in 0.9% of patients.
¶Detachable tip (Sonic) was used.
**NBCA in 3 cases.
††NBCA in 12% of patients.
EVOH, ethylene-vinyl alcohol co-polymer; NA, not available; NBCA, n-butyl cyanoacrylate; PVA, polyvinyl alcohol.